Olema Pharmaceuticals Income Statement (2020-2026) | OLMA

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
39.68M39.80M39.87M39.97M40.08M40.29M40.44M41.12M44.98M45.25M55.87M57.25M57.29M58.74M85.43M68.63M68.65M81.38M87.33M87.50M
Operating items
Research & Development (Quarter)
12.52M15.97M16.01M27.05M17.63M21.58M22.83M17.99M19.45M25.87M29.88M29.11M33.23M32.30M30.62M43.90M39.95M43.22M49.23M57.78M
Selling, General & Administrative (Quarter)
5.24M5.78M7.25M6.24M5.59M5.63M6.78M3.61M3.89M4.54M4.46M4.42M4.39M4.47M4.25M3.96M5.93M6.86M8.75M9.39M
Operating Expenses (Quarter)
17.76M21.76M23.25M33.29M23.22M27.22M29.60M21.60M23.34M30.42M34.34M33.53M37.62M36.77M34.87M47.86M45.88M50.08M57.99M67.18M
Operating Income (Quarter)
-17.76M-21.76M-23.25M-33.29M-23.22M-27.22M-29.60M-21.60M-23.34M-30.42M-34.34M-33.53M-37.62M-36.77M-34.87M-47.86M-45.88M-50.08M-57.99M-67.18M
EBIT (Quarter)
-17.76M-21.76M-23.25M-33.29M-23.22M-27.22M-29.60M-21.60M-23.34M-30.42M-34.34M-33.53M-37.62M-36.77M-34.87M-47.86M-45.88M-50.08M-57.99M-67.18M
Non-operating items
Interest & Investment Income (Quarter)
0.10M0.11M0.22M0.41M0.62M0.97M1.30M1.55M1.92M3.55M3.35M3.11M2.93M3.29M4.52M4.04M3.65M4.01M4.78M4.51M
Other Non Operating Income (Quarter)
-0.06M0.01M0.01M0.02M-0.12M0.07M0.01M-0.04M-0.08M0.09M0.02M0.04M0.14M-0.09M-0.04M0.04M0.01M0.01M0.12M-0.53M
Non Operating Income (Quarter)
0.05M0.12M0.22M0.43M0.50M1.04M1.32M1.51M1.84M3.64M3.37M3.15M3.07M3.20M4.48M4.08M3.66M4.02M4.90M3.98M
Net income details
EBT (Quarter)
-89.42M-42.72M-26.55M-36.40M-25.80M-26.57M-30.33M-51.62M-75.36M-27.13M-71.72M-67.53M-78.93M-33.78M-31.67M-45.75M-42.54M-46.38M-145.10M-131.35M
Profit After Tax (Quarter)
-17.71M-21.64M-24.51M-33.63M-23.00M-25.32M-28.29M-20.09M-21.50M-26.77M-31.33M-30.49M-34.55M-33.57M-30.39M-43.89M-42.22M-46.06M-53.09M-63.69M
Income from Continuing Operations (Quarter)
-89.42M-42.72M-26.55M-36.40M-25.80M-26.57M-30.33M-51.62M-75.36M-27.13M-71.72M-67.53M-78.93M-33.78M-31.67M-45.75M-42.54M-46.38M-145.10M-131.35M
Consolidated Net Income (Quarter)
-89.42M-42.72M-26.55M-36.40M-25.80M-26.57M-30.33M-51.62M-75.36M-27.13M-71.72M-67.53M-78.93M-33.78M-31.67M-45.75M-42.54M-46.38M-145.10M-131.35M
Income towards Parent Company (Quarter)
-89.42M-42.72M-26.55M-36.40M-25.80M-26.57M-30.33M-51.62M-75.36M-27.13M-71.72M-67.53M-78.93M-33.78M-31.67M-45.75M-42.54M-46.38M-145.10M-131.35M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-17.71M-21.64M-26.55M-36.40M-25.80M-26.57M-30.33M-51.62M-75.36M-27.13M-71.72M-67.53M-78.93M-33.78M-31.67M-45.75M-42.54M-46.38M-145.10M-131.35M
Additional items
EPS (Basic) (Quarter)
-0.45-0.55-0.67-0.91-0.64-0.66-0.75-1.27-1.68-0.60-1.29-1.20-1.38-0.58-0.37-0.54-0.50-0.53-1.41-1.26
EPS (Diluted) (Quarter)
-0.45-0.55-0.67-0.91-0.64-0.66-0.75-1.27-1.68-0.60-1.29-1.20-1.38-0.58-0.37-0.54-0.50-0.53-1.41-1.26
Shares Outstanding (Quarter)
39.61M39.52M39.83M39.92M40.04M40.00M40.35M40.72M44.98M45.25M55.57M56.28M57.26M58.74M85.43M85.50M85.73M87.01M102.80M104.45M
Shares Outstanding (Diluted) (Quarter)
39.61M39.52M39.83M39.92M40.04M40.00M40.35M40.72M44.98M45.25M55.57M56.28M57.26M58.74M85.43M85.50M85.73M87.01M102.80M104.45M
EBITDA (Quarter)
-17.76M-21.76M-23.25M-33.29M-23.22M-27.22M-29.60M-21.60M-23.34M-30.42M-34.34M-33.53M-37.62M-36.77M-34.87M-47.86M-45.88M-50.08M-57.99M-67.18M
Interest Expenses (Quarter)
71.76M21.07M3.52M3.52M3.20M0.32M2.03M31.57M53.94M0.26M40.73M37.10M44.23M0.31M1.32M1.93M0.31M0.30M91.89M68.68M